Last reviewed · How we verify
NCT03694067
Androgenetic Alopecia and the JAK-STAT Pathway
trial testing Punch skin biopsy in Androgenetic Alopecia in 25 participants. Completed in 1 December 2019.
1 December 2019
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 15 October 2018 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 December 2019 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Punch skin biopsy
Conditions studied
- Androgenetic Alopecia — all drugs for Androgenetic Alopecia →
Sponsor
Cairo University
Who can join
18 and older, male only, with Androgenetic Alopecia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is a well known fact that the JAK-STAT pathway plays a pivotal role in the pathogenesis of alopecia areata. Both phosphorylated STAT 1 and 3 have been found to be upregulated in the disease. However, whether this pathway plays a role in other hair loss disorders remains unclear. The study aims at assessing STAT3 levels in male patients with androgenetic alopecia. The investigators hypothesize that STAT3 levels will be elevated (due to a previous study proving that JAK-STAT pathway is involved in non-immune mediated hair loss in mice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03694067
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Punch skin biopsy
Trials testing the same drug.
- NCT03685929 — Histopathological Comparison Between Superficial Pressure Ulcers and Incontinence-associated Dermatitis · completed
- NCT02756962 — Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance · Phase 2 · active not recruiting
Other recruiting trials for Androgenetic Alopecia
Currently open trials in the same condition.
- NCT07429253 — Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients · Phase 1, PHASE2 · recruiting
- NCT06841458 — Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers · NA · recruiting
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03694067 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 28 January 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03694067.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing